Important Changes to Opioid Safety Edits with VNSNY CHOICE SelectHealth

Effective October 1, 2019, opioid analgesics are subject to certain safety edits, as described in more detail below.

- The **Opioid Cumulative Dosing at POS** program will deny an incoming claim that puts a member’s cumulative morphine milligram equivalent (MME) dose per day across a single or multiple opioid-containing claim(s) equal to or exceeding a hard-stop threshold of 200 MME or a soft-stop threshold of 90 MME.

- The **Opioid-Benzodiazepine Concurrent Use** program will identify and deny concurrent use of benzodiazepines and opioids when there is any overlap in day supply.

- The **Opioid-Antipsychotic Concurrent Use** program will identify and deny incoming opioid claim only when there is an overlap in day supply of greater than or equal to 8 days with an antipsychotic drug. The edit only applies if there are two or more providers prescribing the medications from different locations.

- The following safety edits will continue to apply:
  - Maximum of four opioid claims approved within 30 days
  - Limit of seven days on an initial fill of short-acting opioids.

Pharmacists will reach out to prescribers to gather information and documentation on opioid utilization and resubmit claims with the appropriate Drug Utilization Review (DUR) codes. You and your staff are encouraged to provide this information when contacted to ensure that there is no interruption in necessary therapies for the beneficiary. Alternatively, a Prior Authorization may be requested by you or your staff.

These edits do not apply if patient is a recipient of hospice or palliative care, has a diagnosis of cancer, is a resident of a long-term care facility, or has any other condition the state elects to treat as exempted from such requirements.

**For more information or assistance in requesting a Prior Authorization, please call:**

**MedImpact**

1-800-788-2949 (TTY: 711)

24 hours a day/7 days a week

Treatment of Opioid Use Disorder clinical guidelines published by the NYS DOH – AIDS Institute:
https://www.hivguidelines.org/substance-use/oud/